In “Risk of Tuberculosis Reactivation With Tofacitinib (CP-690550)” by Maiga et al [J Infect Dis 2012; 205:1705–8], on page 1707 of the Discussion section, the following sentence, “The 1.5 and 15 mg/kg/day doses used in this study have been previously reported in BALB/c mice to have an anti-inflammatory effect, and plasma levels of tofacitinib in mice receiving 15 mg/kg/day were reported to average 61.2 ± 5.75 ng/mL, which is similar to the levels reported in humans receiving a twice-daily 15 mg/kg dose of tofacitinib” should read: “The 1.5 and 15 mg/kg/day doses used in this study have been previously reported in BALB/c mice to have an anti-inflammatory effect, and plasma levels of tofacitinib in mice receiving 15 mg/kg/day were reported to average 61.2 ± 5.75 ng/mL, which is similar to the levels reported in humans receiving a daily 0.15 mg/kg dose of tofacitinib.”

The authors regret this error.